Is Bioxytran Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Bioxytran Inc (BIXT) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Bioxytran Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Bioxytran Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Bioxytran Inc?

Muslim investors may consider investing in Bioxytran Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Bioxytran Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Bioxytran Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Bioxytran Inc updated?

The Shariah compliance status of Bioxytran Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Bioxytran Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Bioxytran Inc?

You can check the latest Shariah compliance status of Bioxytran Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Bioxytran Inc. Stock Analysis BIXT

United States Health Care Nano Cap

BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. The company is headquartered in Needham, Massachusetts. The company went IPO on 2010-01-05. The firm is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The firm's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Key Statistics of Bioxytran Inc (BIXT)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.03$0.03

Today's Open

$0.03

Volume

4000.00

P/E Ratio (TTM)

52 Week Range

$0.03$0.17

Market Cap

2.87M

Avg. Volume

80.59K

Dividend Yield

Financial Metrics & Statements of Bioxytran Inc (BIXT)

FAQ's for Bioxytran Inc (BIXT)

According to Musaffa’s Shariah screening methodology, Bioxytran Inc (BIXT) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.